Flomenberg Neal 4

What Happened
Neal Flomenberg, Tevogen Bio Holdings’ Chief Scientific Officer and Global R&D Lead, reported sales of 972 shares (total proceeds $6,635) in three transactions to satisfy tax withholding on vested restricted stock units. Transactions: 19 shares on 2026-03-10 at $7.75 ($147), 452 shares on 2026-03-11 at a weighted $7.26 ($3,282), and 501 shares on 2026-03-13 at a weighted $6.40 (~$3,206). These were sales (code S) and, per the filing, were made solely to cover tax obligations and not at the reporting person’s discretion.

Key Details

• Transaction dates: 2026-03-10, 2026-03-11, 2026-03-13; Form 4 filed 2026-03-17 (timely).
• Prices and proceeds:
  • 19 sh @ $7.75 = $147
  • 452 sh @ weighted $7.26 = $3,282 (individual trades ranged $7.25–$7.33 per footnote)
  • 501 sh @ weighted $6.40 = $3,206 (individual trades ranged $6.39–$6.74 per footnote)
• Total shares sold: 972; total reported proceeds: ~$6,635.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Notable footnotes: F1 — sales solely to satisfy tax withholding for RSU settlement (not discretionary); F2 — reported prices are weighted averages and detailed per-request; F3/F4 — price ranges for grouped sales.
• Remark/role: Chief Scientific Officer, Global R&D Lead.
• All holdings reported have been adjusted for the 1-for-50 reverse stock split effective March 6, 2026.

Context
These sales were tax-withholding related to RSU settlement (routine, labeled in the filing), which is common and does not necessarily signal a voluntary sell decision. No option exercises, gifts, or 10% owner transactions are indicated. The filing appears timely based on the transaction and filing dates.